Abstract
Objective To conduct the pharmacoeconomic evaluation of lipid-lowering effects of different zhibitai capsules regimens compared with moderate-intensity atorvastatin calcium,and to provide a reference for clinical selection of lipid-lowering drugs.Methods A decision tree model was constructed by the TreeAge Pro 2022.2.1 software.With the per capita disposable income of Sichuan Province in 2024(CNY 34 325)as the willingness to pay(WTP)threshold,and with the decrease in low-density lipoprotein cholesterol(LDL-C)(ΔLDL-C)as the effect parameter,a cost-effectiveness analysis was conducted on the comparison of the Zhibitai Capsules regimens with the moderate-intensity(10 mg or 20 mg)atorvastatin calcium regimens retrieved from the CNKI,WanFang,VIP,SinoMed,Embase,PubMed,and The Cochrane Library databases.Results Through screening,21 articles were included[involving 22 randomized controlled trials(RCTs)],in which compared two Zhibitai Capsules alone regimens and five Zhibitai Capsules combined with atorvastatin calcium regimens with the moderate-intensity atorvastatin calcium regimens,respectively.The incremental cost-effectiveness ratio(ICER)analysis showed that the LDL-C of regimen 1[240 mg of Zhibitai Capsules alone,twice daily(bid)]did not decrease compared to the atorvastatin calcium regimen[10 mg,once daily(qd)],indicating an increase in cost.The ICERs for regimen 2[Zhibitai Capsules(alone,480 mg,bid)],regimen 3[Zhibitai Capsules(480 mg,bid)+atorvastatin calcium(10 mg,qd)],regimen 4[Zhibitai Capsules(240 mg,bid)+atorvastatin calcium(10 mg,qd)]compared to the atorvastatin calcium(10 mg,qd)regimen were-CNY 1 514.48,-CNY 806.25,-CNY 889.66,respectively.The ICERs for regimen 5[Zhibitai Capsules(480 mg,bid)+atorvastatin calcium(10 mg,qd)],regimen 6[Zhibitai Capsules(240 mg,bid)+atorvastatin calcium(20 mg,qd)],and regimen 7[Zhibitai Capsules(480 mg,bid)+atorvastatin calcium(20 mg,qd)]compared to the atorvastatin calcium(20 mg,qd)regimen were-CNY 1 766.40,-CNY 422.95,-CNY 3 685.71,respectively.Conclusion In the case of taking the per capita disposable income of Sichuan Province in 2024 as the WTP threshold,except for the use of Zhibitai Capsules(240 mg,bid)alone was not economically viable compared with moderate-intensity atorvastatin calcium(10 mg or 20 mg,qd),the remaining Zhibitai Capsules regimens in the study were all economically viable compared with moderate-intensity atorvastatin calcium regimens.The research regimens were robust in the variable range of key elements.关键词
脂必泰胶囊/阿托伐他汀钙/成本-效果分析/决策树模型/降脂效果/药物经济性评价Key words
Zhibitai Capsules/atorvastatin calcium/cost-effectiveness analysis/decision tree model/lipid-lowering effect/pharmacoeconomic evaluation分类
医药卫生
